Independent Model Estimates Up To $11,142 in Gross Medical Cost Savings Per Member Over Five Years for Omada’s GLP-1 Program
Independent modeling projects meaningful five‑year cost savings and lower cardiometabolic risk for members in Omada’s GLP‑1 Care Track versus standard care.
Rhea-AI Summary
Omada Health (OMDA) released an independent Markov microsimulation model estimating up to $11,142 in five‑year gross medical cost savings per GLP‑1 member.
The GlobalData analysis used nationally representative datasets plus clinical data from nearly 25,000 Omada GLP‑1 Care Track members to project disease onset and healthcare costs. Members persisting on GLP‑1 therapy for at least 12 months were estimated to save about 30% more at year five than those persisting at least six months ($11,142 vs. $8,578). More engaged members, defined as 9.5+ actions per week, were estimated to save an additional $1,891 at five years. New‑onset type 2 diabetes and hypertension were projected to decline 49% and 28% at five years, with five‑year cumulative savings of $8,578 for the six‑month persistence cohort versus standard care and differentiated savings across age and racial/ethnic groups.
Positive
- Five‑year savings per member up to $11,142 for 12‑month GLP‑1 persistence cohort
- Shorter‑persistence cohort modeled five‑year savings of $8,578 versus standard care
- High‑engagement members estimated extra $1,891 savings at year five ($9,739 vs. $7,848)
- Disease risk reduction modeled 49% lower new‑onset type 2 diabetes and 28% lower hypertension at five years
- Three‑year cumulative savings modeled at $4,784 for six‑month persistence cohort versus standard care
- Modeled five‑year savings by group: $10,969 (65+), $9,971 (Black), $9,107 (Asian), $8,864 (Hispanic), $8,032 (White)
Negative
- None.
Key Figures
- Five-year savings
- $11,142
- Members persisting on GLP-1 medication for at least 12 months
- Five-year savings
- $8,578
- Members persisting on GLP-1 medication for at least 6 months
- Engagement savings
- $1,891
- Additional year-five savings for members with 9.5+ weekly engagement actions
- Type 2 diabetes risk reduction
- 49%
- Projected new-onset reduction at five years
- Hypertension risk reduction
- 28%
- Projected new-onset reduction at five years
- Cumulative savings
- $4,784
- Projected savings at three years for the 6-month persistence cohort versus standard care
- Cumulative savings
- $8,578
- Projected savings at five years for the 6-month persistence cohort versus standard care
- Average weight loss
- 12.4%
- At twelve months in Omada’s GLP-1 solutions
Historical Context
-
Reported first prescribing-program customer and raised 2026 revenue and adjusted EBITDA outlook.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 medical
markov microsimulation model technical
pharmacy benefit manager financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
New model demonstrates the clinical and economic value of medication persistence, companion program engagement, and projected disease risk reduction
SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada’s GLP-1 program.1
GlobalData, a data analytics and consulting company, recently published a report estimating greater disease reduction and higher cumulative cost savings with Omada’s GLP-1 solutions compared to standard care. Using their peer-reviewed Markov microsimulation model approach, the model projects disease-onset trajectories and associated total healthcare savings using data from nationally representative datasets as well as clinical data from nearly 25,000 Omada GLP-1 Care Track members.1
Findings from the simulation model offer a new criteria set for guiding GLP-1 strategy decisions, based on short and long-term value metrics, rather than upfront cost avoidance alone.
- Medication Persistence: Members who stayed on their GLP-1 for at least 12 months were estimated to save around
30% more, on average, at year five than those who persisted for at least 6 months ($11,142 vs.$8,578) .1 - Sustained Lifestyle Engagement: More engaged members (9.5+ engagement actions per week) were estimated to save an additional
$1,891 at year five compared to less engaged members ($9,739 vs.$7,848) .1 - Reduced Disease Risk: New-onset type 2 diabetes was projected to fall
49% and new-onset hypertension to fall28% at five years, with cumulative savings estimated to reach$4,784 at three years and$8,578 at five years for the 6-month persistence cohort versus standard care.1 - Closing Gaps in Chronic Care: Omada’s supportive care program addressing differences in access, health needs, and engagement can help more members benefit from care. Estimated five-year savings were
$10,969 for members 65+,$9,971 for Black members,$9,107 for Asian members, and$8,864 for Hispanic members, compared to$8,032 for White members.1
The model projected cost savings and disease onset reduction over 5 years, taking into account actual persistence levels and clinical outcomes from members in Omada's GLP-1 solutions, including
“Obesity and its downstream conditions have cost employers more every year,2 and we’re reaching a point where employers and members are demanding a care model built for the long run,” said Wei-Li Shao, President at Omada Health. “Omada is the program employers look to when they want someone accountable for long-term health outcomes, not just day-one access, and our GLP-1 program is one of the few in the market that can demonstrate the evidence to back that up."
Omada has spent 15 years as a virtual cardiometabolic provider, and its GLP‑1 Care Track applies that experience to weight health. Published analyses of the program show improvements in body composition alongside overall weight loss.3,4 The wraparound care program combines a human care team, connected devices, and AI‑enabled technology to deliver nutrition, exercise, medication education, and ongoing support to help members build better, sustainable habits. Omada’s GLP‑1 Care Track can be deployed through the nation’s three leading pharmacy benefit manager solutions, direct‑to‑employer programs, and cash-pay options like GLP‑1 Flex Care. Learn more about Omada Health’s approach to GLP-1 medications and coverage here.
About Omada Health
Omada Health, Inc. (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, prediabetes and diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.
Citations:
- GlobalData Healthcare. Value of Integrated Virtual Lifestyle Care Plus GLP-1 Therapy: Modeled Clinical and Economic Outcomes in a Commercially Insured Population. Commissioned by Omada Health; August 2026. Accessed August 30, 2026. https://www.globaldata.com/health-economics/virtual-care/glp1-solutions-report.pdf.
- Telesford I, Schwartz H, Claxton G, Cox C. How have costs associated with obesity changed over time? Peterson-KFF Health System Tracker. Published July 8, 2024. Accessed August 17, 2026. https://www.healthsystemtracker.org/chart-collection/how-have-costs-associated-with-obesity-changed-over-time/
- Stanton LA, Naqvi JB, Devaraj SM, McGuill A, Norwood TA, Linke S. Quality plus quantity: evaluation of a virtual GLP-1 programme with physical activity support to promote healthy body composition change during GLP-1 weight loss. Diabetes Obes Metab. 2026:1-12. doi:10.1111/dom.71152
- Devaraj S, Chang H, Napoleone J, Linke S. Weight health at one year: Outcomes from Omada's Enhanced GLP-1 Care Track. Omada Health. Published January 8, 2026. Accessed August 26, 2026. https://www.omadahealth.com/resource-center/weight-health-at-one-year-outcomes-from-omadas-enhanced-glp-1-care-track
Media Contact
Rose Ramseth
press@omadahealth.com
FAQ
What data sources underlie the new GLP‑1 cost savings model for Omada Health?
The model uses a peer‑reviewed Markov microsimulation approach that projects disease‑onset trajectories and related healthcare costs. It incorporates data from nationally representative datasets and clinical data from nearly 25,000 members enrolled in Omada’s GLP‑1 Care Track, including an observed 12.4% average weight loss at twelve months.
How does member engagement affect modeled savings in Omada’s GLP‑1 program?
Members with at least 9.5 engagement actions per week were projected to save $9,739 at year five, compared with $7,848 for less engaged members. This represents an estimated additional $1,891 in five‑year gross medical cost savings associated with higher program engagement.
How does the model describe savings differences among demographic groups in Omada’s GLP‑1 program?
The model estimated five‑year gross medical cost savings of $10,969 for members aged 65+, $9,971 for Black members, $9,107 for Asian members, and $8,864 for Hispanic members, compared with $8,032 for White members. The company said its supportive care program aims to address differences in access, health needs, and engagement so more members can benefit from care.
In what ways can Omada’s GLP‑1 Care Track be deployed for employers and health plans?
Omada’s GLP‑1 Care Track can be deployed through the three leading pharmacy benefit manager solutions, direct‑to‑employer programs, and cash‑pay options such as GLP‑1 Flex Care. The program combines a human care team, connected devices, and AI‑enabled technology to provide nutrition, exercise, medication education, and ongoing support.